| You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here. Prefer to view this content on our website? Click here.
Dear Fellow Investor, These Obesity Stocks Are Showing Signs of Life Again The race to develop next-generation obesity treatments has created one of the most exciting opportunities in biotech. While big names like Eli Lilly and Novo Nordisk have dominated headlines with their blockbuster drugs, smaller, clinical-stage biotech companies working on innovative GLP-1 agonists and other weight-loss therapies are starting to catch serious investor attention — especially as valuations pull back from previous highs. With obesity now affecting over 40% of U.S. adults, and global demand for effective weight loss drugs surging, the total addressable market could soon surpass $100 billion annually. That’s created an environment where small-cap biotechs with promising data have the potential to become major acquisition targets — or breakout performers in their own right. Obesity is one of the largest and fastest-growing global health challenges — and the market for effective, safe treatments is expected to explode in the next decade. Big players have already reaped the benefits, but now investors are looking toward smaller companies with pipeline potential and upcoming catalysts. Both of the stocks below are at the forefront of this movement, offering: Strong clinical data Oral drug development (a major advantage over injectables) Acquisition and partnership appeal Upcoming trial milestones that could move the stocks significantly If you’re looking for asymmetric upside potential in 2025 and beyond, these two names belong on your biotech watchlist — especially with the obesity drug market heating up again. Here are two under-the-radar obesity treatment stocks that are showing new signs of life — and may be worth a closer look. Mode Mobile One has headlines. The other has 45 million users.
Trump Mobile is here. Gold phones. Flag decals. $499.99 price tags. It’s loud. It’s political. And it’s a pure brand play. But is it scalable? While attention is on the president’s brand, Mode Mobile built something different – and proven. A mobile-first earning ecosystem with 45M+ users 32,481% 3-year revenue growth
$75M+ in revenue — before IPO (ticker $MODE reserved)
50,000+ investors already in (2 previous sold out offerings) One sells symbolism. The other sells revenue from screen time back to users across 170+ countries. Trump may be onstage, but Mode is in their pockets. And for a limited time, accredited investors can get access before Mode’s potential pre-IPO debut. ⌛ Last chance to earn up to 140% bonus shares in Mode - offer closing 7/3. Company: Viking Therapeutics (SYM: VKTX)
Current Price: $27.63 Viking Therapeutics has long been on biotech investors’ radar thanks to its promising GLP-1/GIP dual agonist candidate, VK2735. After a sharp run-up earlier this year, shares have pulled back to more attractive levels — and could soon be gearing up for another major rally. Why? Viking just initiated its Phase 3 VANQUISH clinical program for VK2735, a crucial step in getting the obesity drug to market. VK2735 targets both the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, two proven pathways in weight loss and metabolic improvement. According to CEO Brian Lian, the company isn’t just focused on one delivery method either. In a recent press release, he noted: "Along with the successful initiation of the Phase 3 program, we continue to make progress on VK2735's broader development. This includes our plans to initiate an additional clinical study to evaluate a monthly maintenance regimen, expected to begin later this year. We also expect to report Phase 2 oral dosing data in the second half of this year." In other words, Viking isn’t a one-trick pony. It’s advancing both oral and injectable versions of its obesity drug candidate, which could make it more competitive and convenient for patients if it reaches approval. But that’s not all. There are persistent rumors of buyout potential, with Pfizer (PFE) often mentioned as a possible suitor. Pfizer CEO Albert Bourla has publicly said the company may seek acquisitions in the obesity drug space to rebuild its pipeline — and with Viking’s data looking increasingly promising, VKTX could be a strategic fit. The bottom line: If Viking delivers strong Phase 2 oral results and progresses smoothly through Phase 3 trials, shares could easily double or more — especially if big pharma steps in. Musk's Secret AI Facility Could Change Everything Elon Musk's 750,000 sq ft AI facility in Memphis could be more lucrative than Tesla and SpaceX combined. NVIDIA is quietly investing— And we found a "backdoor" play for everyday investors. Click here to learn how to get in >>>
Company: Structure Therapeutics (SYM: GPCR)
Current Price: $20.99
Structure Therapeutics is another biotech firm gaining traction in the obesity drug arms race. The company recently announced positive topline results from its Phase 2a trial of GSBR-1290, its oral GLP-1 receptor agonist. The data showed a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks. This early data puts GSBR-1290 in a very competitive position in the race to deliver an effective oral weight-loss therapy — a space that many believe is the next frontier in obesity treatment. Encouragingly, Structure isn’t slowing down. The company plans to initiate a Phase 2b, 36-week trial of GSBR-1290 in the fourth quarter of 2025. If that study confirms the current results — or improves on them — GPCR could quickly become one of the most talked-about small-cap biotech stocks in the market. Wall Street is already taking notice: Citigroup just initiated coverage with a Buy rating and a $60 price target Citi analysts also see potential partnership interest in Structure’s oral obesity pipeline, suggesting the company could attract investment — or even acquisition — interest from big pharma At a current price well below Citi’s target, GPCR could offer significant upside — especially for investors willing to ride the data-driven volatility that often defines biotech. Monument Traders Alliance Trump's Stock Warning
Trump just drew a line in the sand. When a powerful U.S. ally moved against ONE American company, Trump didn't hesitate. He issued a direct threat and warned them they were "making a big mistake." Discover why this single company is so valuable that Trump is set to directly attack anyone who messes with it. Find out the story behind this rare stock here. Are there any other obesity/healthcare stocks you're interested in right now? Which ones? What other sectors of the market do you think are on their way up? Hit "reply" to this email and let us know your thoughts! | 